Understanding the biology of malignant rhabdoid tumours to develop targeted treatments
Improved therapeutic targeting in malignant rhabdoid tumours using discovery proteomics analysis
Understanding genetic changes in neuroblastoma cells to pave the way for targeted treatments
Investigation of the effects of DNA repair inhibitors in pre-clinical models of neuroblastomas with ATM, MYCN and TP53 abnormalities
Investigating a new approach to treating childhood brain tumours
Investigating the arginine auxotrophy of paediatric brain tumours
Developing a test to help treat leukaemia that has spread to the brain
Developing leukaemic biomarkers to enable personalised CNS-directed therapy
Improving our understanding of ependymomas in the spinal cord
Comprehensive molecular characterization of paediatric spinal ependymomas
Understanding what goes wrong in cells that leads to malignant rhabdoid tumours
Unravelling the impact of SMARCB1 loss on the chromatin landscape in malignant rhabdoid tumor to identify novel therapeutic opportunities
Understanding the order of genetic changes that lead to Wilms tumour to improve treatment
Ordering of driver mutations in bilateral Wilms’ tumour
Improving our understanding of leukaemia that has spread throughout the body
Defining the tumour microenvironment in extramedullary acute leukaemia
Improving our understanding of how chemotherapy works in hepatoblastoma
Analysis of genome-wide 5-hydroxymethylcytosine patterns in human hepatoblastoma tumours during chemotherapy treatment